You are here:Home-Inhibitors & Agonists-Immunology/Inflammation-NOD-like Receptor (NLR)

Request The Product List ofNOD-like Receptor (NLR) NOD-like Receptor (NLR)

Cat. No. Product Name CAS No. Information
PC-35385

INF39

866028-26-4 INF39 (NLRP3 inhibitor INF39) is a nontoxic, irreversible, orally available NLRP3 inhibitor that inhibits NLRP3 ATPase and decreases interleukin-1β release from macrophages; significantly inhibit ATP- and nigericin-induced IL-1β release in mouse bone marrow derived macrophages (BMDM) at 10 uM, reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats.
PC-35137

CY-09

1073612-91-5 CY-09 (NLRP3 inhibitor CY-09) is a selective and direct NLRP3 inhibitor, binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity; suppresses NLRP3 inflammasome assembly and activation, shows remarkable therapeutic effects on mouse models of cryopyrin-associated autoinflammatory syndrome (CAPS) and type 2 diabetes.
PC-63450

NBC19

2068818-75-5 NBC19 is a potent inhibitor of NLRP3 inflammasome, inhibits nigericin-induced ASC speck formation in post-differentiated THP1 cells with IC50 of 60 nM.
PC-43229

MCC950 sodium

256373-96-3 MCC950 (CP-456773) is a potent, selective, small-molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 and 8.1 nM in BMDM and HMDM, respectively, specifically inhibits activation of NLRP3, does not inhibit NLRC4, AIM2, TLR signalling or priming of NLRP3; blocks NLRP3 induced ASC oligomerization, does not block K+ efflux, Ca2+ flux or NLRP3-ASC interactions; reduces interleukin-1β (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), rescues neonatal lethality in mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome
PC-43228

MCC950

210826-40-7 MCC950 (CP-456773) is a potent, selective, small-molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 and 8.1 nM in BMDM and HMDM, respectively, specifically inhibits activation of NLRP3, does not inhibit NLRC4, AIM2, TLR signalling or priming of NLRP3; blocks NLRP3 induced ASC oligomerization, does not block K+ efflux, Ca2+ flux or NLRP3-ASC interactions; reduces interleukin-1β (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), rescues neonatal lethality in mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome
PC-61787

JC-171

2112809-98-8 JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM; interferes with NLRP3/ASC interaction induced by LPS/ATP stimulation both in vtiro and in vivo; delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE).
PC-42228

NOD-IN-1

132819-92-2 A potent, dual inhibitor of NOD1 and NOD2 with IC50 of 5.74 uM and 6.45 uM, respectively; is 7-fold less potent than Noditinib-1 in terms of NOD1 inhibition and completely devoid of selective activity for NOD1 or NOD2 as opposed to Noditinib-1.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com